Skip to content
Monday 24 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,854.32
+0.35%
DAX
26,106.60
-0.11%
CAC 40
8,453.01
-0.37%
STOXX 50
6,447.98
-0.22%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Tuesday 06 September 2016 6:04 pm

Bayer’s share price jumps two per cent as shareholders react to news of “advanced” Monsanto talks

By: William Turvill

Add as a preferred source on Google

Bayer’s share price jumped two per cent today after the company announced it was in “advanced” talks to acquire US seeds firm Monsanto.

The German chemicals giant’s bid now stands $127.50 per share, or around $65bn (£49bn). This is an improvement on previous offers of $122 and $125, which have been rejected by Monsanto.

But the US firm said in a statement on Monday that it was “engaged in constructive negotiations”.

Read more: Bayer and Monsanto are in "advanced" merger talks

Markus Manns, a portfolio manager at top 20 shareholder Union Investment, told Morning Wire any deal below $130 per share would be “very positive”, with $135 acceptable. He said that anything above $140 would be “very bad”.

Manns added that the latest statement from Bayer looked like a “sign they’re making progress” with the deal.

Andrea Williams, a senior fund manager at Bayer shareholder Royal London Asset Management, said she would be “delighted” if Monsanto agreed to the deal at $127.50, but believes the Germans will have to improve the offer further.

She told Morning Wire Royal London would accept an offer of between $130-135 per share.

This generosity may be needed. Two unnamed Monsanto investors told the Financial Times they would like an offer of more than $130.

Read more: Bayer board to debate making a hostile approach for Monsanto

The offer was not welcomed by all Bayer shareholders, however. Henderson Global Investors is opposed to the German company’s pursuit, having previously said the potential takeover has “called into question… the strength of Bayer as a long term investment”.

And today, fund manager John Bennett told Reuters: “Bayer have backed themselves into a corner. The money would have been better spent buying their own stock. Alas, for shareholders, it was not to be.”

Michael Jewell, healthcare partner at Cavendish Corporate Finance, commented: “We should not exclude the possibility of Bayer increasing its bid if the deal is once again turned down.”

[custom id="166"]

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • M&A

Trending Articles

  • Can debt-ridden Morrisons become a Big Four supermarket again?

  • Ratcliffe’s Ineos saves Runcorn plant

  • As it happened: Stocks rally; US to unveil ‘economic D-Day’ Iran sanctions

  • Amazon says it buys books in bulk to ‘improve products’

  • HMRC mansion tax inspectors to target homes for property valuations

More from Morning Wire

  • FTSE 100 Segro agrees to £14bn takeover by Prologis

    Property
    David Sleath, Chief Executive Officer, delivering a speech at a business conference with a focused expression.
  • Revolut founder’s wealth set to balloon amid talks of share award at $500bn valuation

    Fintech
    Revolut CEO Nik Storonsky speaking at a business conference, wearing a suit and tie, addressing financial innovation.
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Manchester billionaire tables £583m offer for property developer Harworth

    Property
    Harworth Group building exterior with a brick facade and prominent entrance under a blue sky
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Oil price falls but Trump and Iran clash on negotiations claim

    Markets
    Donald Trump smiling in a blue suit and tie with an American flag pin, US flag in background
  • As it happened: Oil prices tumble as Bessent says US-Iran deal imminent; miner stocks rally

    Markets
    Scott Bessent, a man with gray hair and glasses, wearing a blue suit and striped tie, looking to the side.
  • Shareholder backlash pushes up low-ball London takeover bids

    Markets
    Over 100 major London-listed companies, including Fevertree Drinks and YouGov, have written to the Chancellor warning that the uncertainty surrounding the future of a key tax relief tied to London’s junior stock market is battering investor confidence. 
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook